Cue Biopharma
47 hedge funds and large institutions have $11.9M invested in Cue Biopharma in 2025 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
47
Holders Change
-2
Holders Change %
-4.08%
% of All Funds
0.63%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
10
Reduced
10
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
1 |
GWMR
GC Wealth Management RIA
Cambridge,
Massachusetts
|
+$2.27M |
2 |
BL
Bleichroeder LP
New York
|
+$1.24M |
3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$594K |
4 |
UBS Group
Zurich,
Switzerland
|
+$158K |
5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$105K |
Top Sellers
1 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
-$185K |
2 |
BlackRock
New York
|
-$127K |
3 |
HighTower Advisors
Chicago,
Illinois
|
-$117K |
4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$107K |
5 |
Northern Trust
Chicago,
Illinois
|
-$43.7K |